Gotham Asset Management LLC Grows Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Gotham Asset Management LLC raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 11.8% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 31,359 shares of the medical research company’s stock after acquiring an additional 3,303 shares during the period. Gotham Asset Management LLC’s holdings in IQVIA were worth $6,162,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in IQV. JPMorgan Chase & Co. grew its holdings in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after buying an additional 583,396 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after buying an additional 56 shares in the last quarter. Czech National Bank grew its holdings in IQVIA by 6.0% during the 4th quarter. Czech National Bank now owns 37,386 shares of the medical research company’s stock valued at $7,347,000 after buying an additional 2,107 shares in the last quarter. Claro Advisors LLC purchased a new stake in IQVIA during the 4th quarter valued at approximately $281,000. Finally, Pallas Capital Advisors LLC purchased a new stake in IQVIA during the 4th quarter valued at approximately $298,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on IQV shares. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. UBS Group cut their target price on shares of IQVIA from $255.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Stifel Nicolaus cut their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Hsbc Global Res lowered shares of IQVIA from a “strong-buy” rating to a “hold” rating in a report on Friday, April 25th. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $231.71.

IQVIA Stock Down 3.5%

NYSE:IQV opened at $150.74 on Wednesday. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a market cap of $26.08 billion, a price-to-earnings ratio of 20.10, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The stock has a fifty day simple moving average of $162.61 and a 200-day simple moving average of $187.42. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same period last year, the company earned $2.54 earnings per share. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.